NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)
$0.84
-0.0799 ( -8.65% ) 497.7K
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Market Data
Open
$0.84
Previous close
$0.92
Volume
497.7K
Market cap
$15.85M
Day range
$0.80 - $0.95
52 week range
$0.40 - $2.33
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 3 | Jul 09, 2024 |
6-k | Quarterly Reports | 1 | Jul 03, 2024 |
6-k | Quarterly Reports | 3 | Jul 01, 2024 |
6-k | Quarterly Reports | 3 | Jun 27, 2024 |
6-k | Quarterly Reports | 3 | Jun 24, 2024 |
6-k | Quarterly Reports | 3 | Jun 21, 2024 |
6-k | Quarterly Reports | 90 | Jun 17, 2024 |
6-k | Quarterly Reports | 6 | May 28, 2024 |
6-k | Quarterly Reports | 3 | May 23, 2024 |
6-k | Quarterly Reports | 4 | May 20, 2024 |